Phosphoinositide 3-Kinases Upregulate System \( x_c^- \) via Eukaryotic Initiation Factor 2\(\alpha\) and Activating Transcription Factor 4 – A Pathway Active in Glioblastomas and Epilepsy

Jan Lewerenz,1 Paul Baxter,2 Rebecca Kassubek,1 Philipp Albrecht,3 Joeri Van Liefferinge,4 Mike-Andrew Westhoff,5 Marc-Eric Halatsch,6 Georg Karpel-Massler,6 Paul J. Meakin,7 John D. Hayes,7 Eleonora Aronica,8,9 Ilse Smolders,4 Albert C. Ludolph,1 Axel Methner,10 Marcus Conrad,11 Ann Massie,12 Giles E. Hardingham,2 and Pamela Maher13

Abstract

**Aims:** Phosphoinositide 3-kinases (PI3Ks) relay growth factor signaling and mediate cytoprotection and cell growth. The cystine/glutamate antiporter system \( x_c^- \) imports cystine while exporting glutamate, thereby promoting glutathione synthesis while increasing extracellular cerebral glutamate. The aim of this study was to analyze the pathway through which growth factor and PI3K signaling induce the cystine/glutamate antiporter system \( x_c^- \) and to demonstrate its biological significance for neuroprotection, cell growth, and epilepsy. **Results:** PI3Ks induce system \( x_c^- \) through glycogen synthase kinase 3\(\beta\) (GSK-3\(\beta\)) inhibition, general control non-derepressible-2-mediated eukaryotic initiation factor 2\(\alpha\) phosphorylation, and the subsequent translational up-regulation of activating transcription factor 4. This pathway is essential for PI3Ks to modulate oxidative stress resistance of nerve cells and insulin-induced growth in fibroblasts. Moreover, the pathway is active in human glioblastoma cells. In addition, it is induced in primary cortical neurons in response to robust neuronal activity and in hippocampi from patients with temporal lobe epilepsy. **Innovation:** Our findings further extend the concepts of how growth factors and PI3Ks induce neuroprotection and cell growth by adding a new branch to the signaling network downstream of GSK-3\(\beta\), which, ultimately, leads to the induction of the cystine/glutamate antiporter system \( x_c^- \). Importantly, the induction of this pathway by neuronal activity and in epileptic hippocampi points to a potential role in epilepsy. **Conclusion:** PI3K-regulated system \( x_c^- \) activity is not only involved in the stress resistance of neuronal cells and in cell growth by increasing the cystine supply and glutathione synthesis, but also plays a role in the pathophysiology of tumor- and non-tumor-associated epilepsy by up-regulating extracellular cerebral glutamate. Antioxid. Redox Signal. 20, 2907–2922.

1Department of Neurology, Ulm University, Ulm, Germany.
2Center for Integrative Physiology, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
3Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
4Pharmaceutical Chemistry and Drug Analysis, Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium.
5University Children’s Hospital, Ulm University, Ulm, Germany.
6Department of Neurosurgery, Ulm University, Ulm, Germany.
7Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom.
8Department of (Neuro)Pathology, Academic Medical Center, and Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Amsterdam, The Netherlands.
9SEIN—Stichting Epilepsie Instellingen Nederland, Heemstede, The Netherlands.
10Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn²), Department of Neurology, Johannes Gutenberg University Medical Center Mainz, Mainz, Germany.
11Institute of Developmental Genetics, Helmholtz Zentrum München, Neuherberg, Germany.
12Pharmaceutical Biotechnology and Molecular Biology, Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium.
13Cellular Neurobiology Laboratory, Salk Institute for Biological Studies, La Jolla, California.
**Innovation**

Phosphoinositide 3-kinases (PI3Ks) as well as system $x_{-}$ have been shown to induce cell growth (48) and neuroprotection (36, 58, 70, 72). In addition, both PI3Ks and system $x_{-}$ are involved in tumor growth (62, 66). We show that PI3Ks induce system $x_{-}$ through general control non-derepressible-2-mediated eukaryotic initiation factor 2x phosphorylation and activating transcription factor 4 translation. The pathway is important for the neuroprotective and growth-stimulatory effects of PI3K activation, is active in glioblastoma cells and, as it is induced by robust neuronal activity in neurons and in human epileptic hippocampi, it might be involved in the pathophysiology of epilepsy.

**Introduction**

Different kinds of intracellular stress are relayed through phosphorylation of the eukaryotic initiation factor 2x (eIF2x) by one of the following four eIF2x kinases: protein kinase R (PKR), heme-regulated eIF2x kinase (HRI), PKR-like endoplasmic reticulum kinase (PERK) and general control non-derepressible-2 (GCN2), and subsequent translational up-regulation of activating transcription factor 4 (ATF4) (61). The mechanism underlying the translational up-regulation of ATF4 is based on two upstream open reading frames (ORFs) within the 5' untranslated region (5'UTR) of its mRNA, the second of which overlaps with the ATF4 ORF and inhibits ATF4 protein synthesis when eIF2x phosphorylation is low (22). The re-establishment of cellular homeostasis by system xc$^{-}$-induced gene transcription is called the integrated stress response (ISR) (3).

ATF4 activates the transcription of genes that are involved in amino-acid import, glutathione (GSH) biosynthesis, and resistance against oxidative stress (23), including xCT mRNA, which encodes the light chain of the amino-acid transporter, system $x_{-}$ (62). System $x_{-}$ imports cysteine into cells while exporting glutamate in a 1:1 ratio (64). Intracellularly, cysteine is reduced to cysteine, which is limiting for the synthesis of the important antioxidant GSH (51). Due to its high concentration, the ratio of reduced GSH to oxidized GSH (glutathione disulfide [GSSG]) determines the overall intracellular redox state (67).

We recently reported that the eIF2x/ATF4/xCT signaling module is an important determinant of the oxidative stress resistance of cells (39). However, in the brain, system $x_{-}$ might represent a double-edged sword, as its activity increases in extracellular glutamate (15) and can, therefore, positively regulate epileptic activity, which depends on ATF4h in these cells (40), nor did it increase glutamate sensitivity (Fig. 1D, left panel). Moreover, LY treatment had no effect on system xc$^{-}$ activity, which depends on ATF4h, in these cells (40), nor did it increase glutamate sensitivity (Fig. 1D, middle and right panels). Thus, translational down-regulation of ATF4 is a prerequisite for the LY-mediated reduction in system $x_{-}$ activity and the exacerbation of oxidative glutamate toxicity.

PI3Ks regulates eIF2x phosphorylation and ATF4 levels through inhibition of GSK-3β in HT22 cells

LY inhibits several kinases that are related to PI3K (17). However, intracellular delivery of PI3P (73), the PI3K product, and transient over-expression of the constitutively active PI3K

Here, we show that the PI3K/Akt/GSK-3β pathway is linked to the activation of the eIF2x/ATF4/xCT signaling module, a connection which is not only important in the pro-proliferative and neuroprotective effects of PI3K signaling but might also play a role in epilepsy.

**Results**

The PI3K inhibitor LY294002 sensitizes HT22 cells to oxidative glutamate toxicity through down-regulation of the eIF2x/ATF4/xCT signaling module

Recently, we demonstrated that eIF2x phosphorylation is a major determinant of oxidative stress resistance by regulating ATF4 protein levels and system $x_{-}$ activity (39). While examining how the eIF2x/ATF4/xCT signaling module is connected to other neuroprotective pathways, we found that the broad-spectrum PI3K inhibitor LY294002 (LY) rapidly and dose dependently down-regulates eIF2x phosphorylation and ATF4 in hippocampal HT22 cells (Fig. 1A, Supplementary Fig. 1A). When transfected with a luciferase (Luci) reporter construct containing the ATF4 5'UTR and AUG of the ATF4 ORF fused to Luci in a pGL3 backbone (22), relative Luci activity was decreased by >50% in HT22 cells that were treated with LY as compared with control cells (Fig. 1B, upper panel). However, a 24 h treatment with LY did not down-regulate ATF4 mRNA (Fig. 1B, lower panel). These findings confirm that ATF4 is down-regulated by LY due to decreased translation. Next, we asked whether LY also reduces xCT expression and system $x_{-}$ activity. A 24 h treatment with LY decreased xCT mRNA expression by ~80% and system $x_{-}$ activity by ~50% (Fig. 1C, left panel). Consistent with these observations, we detected an ~20% decrease in total GSH levels and an ~1.7-fold decrease in the GSH/GSSG ratio on a 24 h treatment with LY (Fig. 1C, middle panels). System $x_{-}$ expression determines the resistance of HT22 cells to oxidative glutamate toxicity (37, 40). Correspondingly, LY pre-treated HT22 cells were significantly more sensitive to oxidative glutamate toxicity when measured by the MTT assay (Fig. 1C, right panel) with trypan blue exclusion and visual inspection yielding similar results (Supplementary Fig. S2; Supplementary Data are available online at www.liebertpub.com/ars).

To confirm that the observed LY-mediated translational down-regulation of ATF4 is essential for decreased system $x_{-}$ activity and increased glutamate sensitivity, we used the HT22-derived line HT22R in which a deletion in the second ORF within the ATF4 5'UTR leads to the expression of a second ORF–ATF4 fusion protein (ATF4h) that is not regulated by eIF2x phosphorylation (40). In HT22R cells, LY suppressed eIF2x phosphorylation but ATF4h levels did not decrease (Fig. 1D, left panel). Moreover, LY treatment had no effect on system $x_{-}$ activity, which depends on ATF4h in these cells (40), nor did it increase glutamate sensitivity (Fig. 1D, middle and right panel). Thus, translational down-regulation of ATF4 is a prerequisite for the LY-mediated reduction in system $x_{-}$ activity and the exacerbation of oxidative glutamate toxicity.

**Discussion**

The PI3K/Akt/GSK-3β pathway is linked to the activation of the eIF2x/ATF4/xCT signaling module, a connection which is not only important in the pro-proliferative and neuroprotective effects of PI3K signaling but might also play a role in epilepsy.
FIG. 1. The PI3K inhibitor LY294002 sensitizes HT22 cells to oxidative glutamate toxicity through down-regulation of the eIF2α/ATF4/ xCT signaling module. (A) Western blotting for phospho-Ser51 eIF2α (p-eIF2α) and ATF4 using cytosolic and nuclear extracts, respectively, of HT22 cells incubated with LY at the indicated concentrations or durations. Total eIF2α (eIF2α) and actin served as loading control for phospho-eIF2α and ATF4, respectively. [B], upper panel] ATF4 translation assessed by the relative luciferase activity in HT22 cells co-transfected with ATF4 5'UTR luciferase (Luc) reporter and Gal plasmids treated with 10 μM LY or vehicle for 24 h. [B], lower panel] ATF4 mRNA abundance in HT22 cells treated with 10 μM LY for 24 h. (C) xCT mRNA abundance (left upper panel), system x̄− activity (left lower panel), total GSH (central panel, upper graph), GSH/GSSG ratio (central panel, lower graph), and survival in response to oxidative glutamate toxicity (right panel) of HT22 cells exposed to LY or vehicle for 24 h measured by the MTT assay. Similar results were obtained by visual inspection and trypan blue exclusion assays (see Supplementary Fig. S2). (D) Western blotting as in (A) using HT22R cells treated with either 10 μM LY or vehicle for 4 h (left panel). System x̄− activity (central panel) and sensitivity against oxidative glutamate toxicity (right panel) in HT22R cells treated with 10 μM LY or vehicle for 24 h. The graphs represent the mean ± SEM of three [(A), upper and lower left panels; (D), lower left panel and right panel], four [(B, C), left and right panels; (D), middle panel], four to five [(A), lower right panel], five [(D), upper left panel], and six [(C), middle panel] independent experiments. Statistical analysis was performed using one way ANOVA with Bonferroni’s post test compared with vehicle treatment (A), one sample t-test [(B–D) left and middle panels], or two-way ANOVA with Bonferroni’s post test [(C, D), right panels], *p<0.05, **p<0.01, and ***p<0.001. 5'UTR, 5' untranslated region; ANOVA, analysis of variance; ATF4, activating transcription factor 4; eIF2α, eukaryotic initiation factor 2α; GSH, glutathione; PI3K, phosphoinositide 3-kinase; SEM, standard error of the mean.

p110α (7) increased eIF2α phosphorylation and ATF4 expression (Fig. 2A, B), supporting the idea that the LY effect is mediated through PI3Ks. To analyze which PI3K isoform mediates the observed effect of LY, we focused on PI3Kα and β, which are expressed in all cells while PI3Kγ and δ play specific roles in the immune system (48). Two structurally unrelated PI3K inhibitors, PIK-90, which preferentially inhibits PI3Kα (IC50 PI3Kα 0.011 vs. PI3Kβ 0.35 μM, PI3Kγ 0.018 μM, and PI3Kδ 0.058 μM) (48), and TGX-221, which preferentially inhibits PI3Kβ (IC50 PI3Kα 0.784 vs. PI3Kβ 0.010 μM, PI3Kγ
PI3Kα regulates elf2α phosphorylation and ATF4 activity and xCT expression in hippocampal HT22 cells. (A) Relative elf2α phosphorylation (p-elf2α) and ATF4 expression in HT22 cells exposed to PIP3 at the indicated concentrations for 1 h. Total elf2α and actin were used as Western blot loading controls, respectively. (B, C) Relative Akt, GSK-3β, and elf2α phosphorylation as well as ATF4 expression assessed by Western blotting in HT22 cells (B) transfected with the constitutively active PI3K p110α (C) treated with the indicated concentrations of TGX-221 or PIK-90 for 2 h. Cytosolic extracts were used for Western blotting for phospho-Ser473-Akt (p-Akt), Akt, phospho-p110α (p-AKT), p-eIF2α, and elf2α and nuclear extracts for ATF4 blotting with actin as a loading control. Vertical white lines indicate the juxtaposition of non-adjacent lanes from the same gel (same exposure). (D) Relative luciferase activity in HT22 cells transfected as in Figure 1B treated with 1 μM PIK-90 or vehicle (Ctrl) for 24 h. (E) System x−c activity in HT22 cells treated with 1 μM PIK-90 or vehicle for 15 h. (F) Expression of the four PI3K catalytic subunits in HT22 cells. The graphs represent the mean ± SEM of three (A–B, C right panels (except elf2α: N=4)) F; (E) and four (C, left panels (except elf2α: N=3); (D) independent experiments. Statistical analysis was performed using one-way ANOVA with Bonferroni’s post test compared with vehicle treatment (A, C) or one sample t-test compared with 1 (B, D) or 100 (E), *p<0.05, **p<0.01, and ***p<0.001. GSK-3β, glycogen synthase kinase 3β; PIP3, phosphoinositide 3,4,5-triphosphate.

3.24 μM, and PI3Kδ 0.065 μM (28, 48), were tested. Treatment of HT22 cells with 0.03 μM PIK-90 for 2 h significantly reduced Akt phosphorylation (Fig. 2C, right panel), whereas 1 μM TGX-221 had little effect (Fig. 2C, left panel). A similar pattern was seen for the downstream targets GSK-3β, elf2α, and ATF4 (Fig. 2C). PIK-90 also reduced Luci activity after transfection with the ATF4 5′UTR Luci reporter construct (Fig. 2D), verifying reduced ATF4 translation and decreased system x−c activity by ~50% (Fig. 2E). Of note, quantitative polymerase chain reaction (qPCR) showed that HT22 express the p110δ subunit of PI3K but not the p110α subunit (Fig. 2F and Supplementary Fig. S3). In combination with the IC50s of PIK-90 and TGX221 for the different p110 isoforms, this indicates that PI3Kα determines the activity of the PI3K pathway in these cells, as inhibition of PI3Kγ cannot explain the effect of PIK90 because p110γ is not expressed and both PI3Kβ and δ are sensitive to TGX221, which has no effect (Supplementary Table S1).

The PI3K pathway leads to the inactivating phosphorylation of GSK-3β (13). Thus, GSK-3β inhibition should mimic the effect of PI3K activation on the elf2α/ATF4/xCT signaling module. Indeed, 20 mM lithium chloride (LiCl), a GSK-3β inhibitor (19, 33), strongly induced elf2α phosphorylation, ATF4 protein expression (Fig. 3A), and ATF4 5′UTR translational activity in the presence as well as the absence of LY; while the effect of LiCl on ATF4 mRNA levels was not significant (Fig. 3B). Moreover, LiCl increased xCT mRNA expression, system x−c activity, cellular GSH, and survival in response to glutamate (Fig. 3C–E). Moreover, siRNA-mediated GSK-3β knock-down (Fig. 3G) and the GSK-3β inhibitors (27,33,E)-6-bromoisindirubin-3'-oxime and CT99021 (Supplementary Fig. S4) yielded results similar to those with LiCl. To substantiate the hypothesis that the regulation of system x−c activity is crucial for the PI3K/GSK3β pathway to influence GSH levels and sensitivity to glutamate, we used mouse embryonic fibroblasts (MEFs) derived from xCT−/− mice which were stably transfected with xCT driven by a CMV/chicken β actin promoter (pCAGxCT MEFs, see Supplementary Materials and Methods) as previously described for HH514 Burkitt’s Lymphoma cells (4). As expected, 10 μM LY significantly down-regulated system x−c activity in wild-type MEFs, an effect that was more than reversed by 20 mM LiCl, whereas no significant changes in system x−c activity by these two compounds were detected in pCAGxCT MEFs (Fig. 3H). Matching patterns were observed for GSH levels (Fig. 3I) and the sensitivity to glutamate (Fig. 3J), although LY did not exacerbate cell death in both cell lines but LiCl only protected in the wild-type MEFs.

The elf2α/ATF4 pathway is involved in the neuroprotective as well as the pro-proliferative action of insulin, possibly by regulating the cellular redox potential.

Insulin signals through the PI3K/Akt/GSK-3β signaling pathway (13) and has been shown to be neuroprotective (26, 72). In HT22 cells, 100 nM insulin induced elf2α phosphorylation and ATF4 levels within 2 h (Fig. 4A). Moreover, insulin robustly induced system x−c activity ~2.5-fold on 24 h of exposure (Fig. 4B). These effects were largely reduced in the presence of LY. The increased x−c activity in response to insulin was accompanied by increased resistance against oxidative glutamate toxicity (Fig. 4C). Growth factors such as
FIG. 3. PI3K-regulated phospho-eIF2α- and ATF4-dependent xCT and system x− expression is mediated via GSK-3β inhibition. (A) Relative eIF2α phosphorylation (p-eIF2α) and ATF4 expression in HT22 cells treated with either 20 mM LiCl or NaCl in combination with either 10 μM LY or vehicle for 4 h. (B) Relative luciferase activity (upper panel) in HT22 cells co-transfected with the ATF4 5′UTR luciferase (Luci) reporter and a Gal control plasmid and relative ATF4 mRNA abundance (lower panel) in HT22 cells, both treated as in (A) but for 24 h. (C, D) xCT mRNA abundance (C) and system x− activity (D) in HT22 cells treated as in (B). (E) Relative GSH levels in HT22 cells treated as in (B) before exposure to 1 mM glutamate for 6 h. (F) Survival in response to 1 mM glutamate of HT22 cells treated as in (B) before exposure to glutamate for 24 h. (G) Relative GSK-3β expression, eIF2α phosphorylation, and ATF4 expression in HT22 cells transfected with siRNA specific for GSK-3β or control siRNA (Ctrl). (H, I) Relative (H) system x− activity and total GSH (I) in response to 24 h of 10 μM LY and additional 20 mM LiCl in WT and pCAGxCT MEFs. The basal relative system x− activity and cellular GSH levels of pCAGxCT MEFs compared with wild-type MEFs were 15.8- and 4.1-fold higher, respectively. (J) The effect of 24 h pre-treatment with 10 μM LY or LY plus 20 mM LiCl on the sensitivity of WT (left graph) and pCAGxCT MEFs (right graph). The graphs show the mean ± SEM of five to seven (A, upper panel), six (J, right graph), four to five (A, lower panel, I, four (B, upper panel/D, E, G, middle and lower panel/H, I), and three (B, lower panel, C, F, G, upper panel, J, left graph) experiments. For (F), the survival of cells treated with NaCl and vehicle in the presence of 1 mM glutamate of each experiment was normalized to the mean survival (12.9%) of all experiments under these conditions. Total eIF2α or actin served as Western blot loading controls. Statistical analysis was performed using two-way ANOVA with Bonferroni’s post test with LiCl-treated cells compared with cells with NaCl treatment (A–F) or by comparing Veh/NaCl with Ly/NaCl and Ly/NaCl with Ly/LiCl (H, I) or one-sample t-test compared with 1 (G), *p < 0.05, **p < 0.01, and ***p < 0.001. GSH, glutathione; LiCl, lithium chloride; MEF, mouse embryonic fibroblast; WT, wild type.
insulin also promote cell proliferation and protein synthesis (57). In response to insulin, increased GSH synthesis enabled by the induction of the eIF2α/ATF4/xCT pathway (39) might lead to a more reduced cellular redox environment, which will, in turn, support cell proliferation (67). Indeed, the complete absence of the eIF2α/ATF4 signaling module in MEFs expressing a genetically engineered eIF2α mutant where the phosphorylation site is inactivated by changing Serine 51 to Alanine (eIF2α S51A) (68) reversed the growth stimulatory effect of insulin observed in wild-type MEFs (Fig. 4D). Correspondingly, siRNA-mediated knock-down of ATF4 (40) strongly decreased cell proliferation by ~40%, an effect that was completely reversed by augmenting cellular GSH (Fig. 4E). In addition, knock-down of ATF4 lowered the GSH/GSSG ratio (Fig. 4F), a change indicative of a more oxidized intracellular redox environment (67).

**FIG. 4.** The eIF2α/ATF4 pathway is involved in the insulin-induced LY-sensitive up-regulation of system xc− and protection against oxidative glutamate toxicity as well as in the pro-proliferative activity of insulin. (A) Relative eIF2α phosphorylation and ATF4 expression in HT22 cells grown in medium with 0.5% FCS and treated with 100 nM insulin with or without 10 μM LY for 4 h. Total eIF2α or actin served as loading controls. (B, C) System xc− activity and survival in response to 10 μM glutamate in HT22 cells grown and treated as in (A) but for 24 h. The survival of vehicle-treated cells was normalized to the mean survival of all experiments (23.8%) under these conditions. (D) Relative cell growth over 48 h in response to 200 ng/ml insulin in WT and eIF2α S51A MEFs. (E, F) HT22 cells were transfected with control siRNA (Ctrl siRNA) or siRNA against ATF4. Twenty-four hours after transfection, cells were re-plated and grown for 48 h. (E) Relative cell number in control and ATF4 siRNA-transfected cells in the presence or absence of 2 mM GSH or 1 mM GEE. (F) The GSH/GSSG ratio of control and ATF4 siRNA-transfected cells calculated as a measure of the cellular redox status. The graphs represent the mean ± SEM of three (A, B, F), four (C), five (E), and three to five (D) independent experiments. Statistical analysis was performed by two-way ANOVA with Bonferroni’s post test with insulin treatment compared with control in the presence or absence of LY (A–D) and ATF4 siRNA compared with control siRNA (E) or by one-sample t test (F), *p < 0.05, **p < 0.01, and ***p < 0.001. FCS, fetal calf serum; GEE, glutathione ethyl ester; GSSG, glutathione disulfide.

**GCN2-mediated eIF2α phosphorylation is essential for the regulation of ATF4 and system xc− activity via PI3K/GSK-3β signaling, while nuclear factor (erythroid-derived 2)-like 2 is not involved**

PI3K has been reported to up-regulate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) (11, 30), which also up-regulates xCT mRNA expression and, thus, system xc− (63). However, LY did not down-regulate basal Nrf2 levels in HT22 cells (Fig. 5A). To further examine whether the PI3K/Akt/GSK-3β pathway depends on eIF2α phosphorylation or Nrf2 to regulate system xc− activity, we used MEFs derived from Nrf2 knockout (~Nrf2−/−) mice (63) and the eIF2α S51A MEFs. Consistent with previous findings that both Nrf2 and eIF2α phosphorylation induces xCT expression (36, 39), basal system xc− activity was reduced to ~41% and ~8% of control activity in Nrf2−/− and eIF2α S51A MEFs, respectively (Fig. 5B,
FIG. 5. GCN2-mediated eIF2α phosphorylation is essential for the regulation of ATF4 and system x_c^- activity via PI3K/
GSK-3β signaling, while Nrf2 is not involved. (A) Nuclear Nrf2 and ATF4 levels in HT22 cells treated with 10 μM LY for 2 h
with actin as a Western blot loading control. (B) System x_c^- activity in WT, Nrf2^-/-, or eIF2α^S51A MEFs treated with PIK-90 and
LY with 20 mM NaCl or LY in combination with 20 mM LiCl for 24 h. (C) Nuclear ATF4 levels in WT, PKR^-/-, PERK^-/-,
HRI^-/-, and GCN2^-/- MEFs treated with vehicle (veh), 10 μM LY (LY), 20 mM LiCl (Li), or a LiCl and LY for 4 h. Actin served
as a loading control. (D) Phosphorylation of eIF2α in cytosolic extracts from GCN2^-/- and GCN2^+/- MEFs treated as in (C)
with total eIF2α as a loading control. (E) GCN2 phosphorylation as a surrogate marker for its activity. HT22 cells were treated as
indicated in (C), and then, cell lysates were prepared and GCN2 was immunoprecipitated with a rabbit GCN2 antibody and
protein A-Sepharose. The immunoprecipitates were blotted with either an antibody to phospho-GCN2 (p-GCN2) or an
antibody to total GCN2 (GCN2). (F) Regulation of system x_c^- activity, total GSH, and resistance against oxidative glutamate
toxicity by the PI3K/GSK-3β pathway in GCN2^-/- compared with GCN2^+/- MEFs. After a 24 h treatment with PI3K
inhibitors and LiCl as in (B) system x_c^- activity and total GSH were measured. Relative system x_c^- activity and
relative total GSH in GCN2^-/- compared with GCN2^+/- was 79% and 109%, respectively. (right panel) GCN2^-/- and
GCN2^+/- MEFs were seeded onto 96-well plates and after 24 h, they were treated with indicated concentrations of glutamate
for 24 h before survival was quantified by the MTT assay. Mean survival of GCN2^-/- was 74.1% at 2.5 mM glutamate, while
GCN2^+/- MEFs showed 70% viability at 50 mM (Supplementary Fig. S5). Relative effect on survival of LY and LiCl at these
glutamate concentrations (GCN2^+/- MEFs 50 mM, GCN2^-/- MEFs 2.5 mM). The graphs represent the mean±SEM of three
[<sup>(F), left panel</sup>], four [<sup>(F), middle and right panel</sup>], five (<sup>(A)</sup>), or four to six independent experiments (<sup>(B)</sup>). The non-quantified Western
blots show representative results from at least three independent experiments. Statistical analysis was performed by a one-
sample t test (<sup>(A)</sup>), one-way ANOVA (<sup>(B)</sup>), or two-way ANOVA (<sup>(F)</sup>) with Bonferroni's post tests:*p<0.05, **p<0.01, and
***p<0.001. GCN2, general control non-derepressible-2; HRI, heme-regulated eIF2α kinase; Nrf2, nuclear factor (erythroid-
derived 2)-like 2; PERK, PKR-like endoplasmic reticulum kinase; PKR, protein kinase R.
left panel). Both PIK-90 and LY suppressed and LiCl rescued the LY effect on system x\textsubscript{-}c\textsuperscript{−} activity equally in wild-type and Nrf2\textsuperscript{−/−} MEFs (Fig. 5B, right panel). In contrast, in elf2\textsuperscript{S51A} MEFs, no changes in system x\textsubscript{-}c\textsuperscript{−} activity were detected with any of these compounds.

We next asked how the PI3K/Akt/GSK-3/β and elf2\textsubscript{a}/ATF4/ xCT pathways were connected. LY down-regulated and LiCl increased ATF4 expression in MEFs from wild-type, PKR\textsuperscript{−/−}, PERK\textsuperscript{−/−}, and HRI\textsuperscript{−/−} mice, whereas this effect was completely abolished in MEFs deficient in the elf2\textsubscript{a} kinase GCN2 (Fig. 5C). Phosphorylation of elf2\textsubscript{a} was reduced by LY and increased by LiCl in wild-type MEFs, but no response to either of these treatments was seen in GCN2\textsuperscript{−/−} MEFs (Fig. 5D). Activation of GCN2 leads to its autophosphorylation (60). In HT22 cells, GCN2 phosphorylation was decreased by LY and increased by LiCl (Fig. 5E). Downstream, the suppression of system x\textsubscript{-}c\textsuperscript{−} activity by either PIK-90 or LY was largely reduced in GCN2\textsuperscript{−/−} MEFs compared with GCN2\textsuperscript{+/+} MEFs and the opposing effect of LiCl was even reversed. A similar pattern was observed for total GSH in response to LY and LiCl (Fig. 5F). GCN2\textsuperscript{−/−} cells were considerably more sensitive to glutamate. When glutamate concentrations were used that led to a similar decrease in activity in MEFs (Fig. 5B, right panel), in contrast, in elf2\textsubscript{a}\textsuperscript{S51A} MEFs, no changes in system x\textsubscript{-}c\textsuperscript{−} activity were detected with any of these compounds.

PI3Ks regulate xCT expression and system x\textsubscript{-}c\textsuperscript{−} activity via elf2\textsubscript{a} phosphorylation and ATF4 in glioblastoma cells

Glioblastomas are highly malignant brain tumors in which the PI3K pathway is frequently hyperactive (16), and both ATF4 (6) and xCT (65) have been found to be up-regulated. Increased system x\textsubscript{-}c\textsuperscript{−} activity in glioblastomas has been linked not only to invasive growth but also to tumor-induced epilepsy (9, 63-66, 72, 74). Indeed, as described for regular glioma cell lines (12, 53), pharmacological inhibition of system x\textsubscript{-}c\textsuperscript{−} activity by two structurally different inhibitors, sulfasalazine and (S)-4-carboxyphenylglycine, also reduced proliferation of serum-differentiated cells derived from glioblastoma-initiating cancer stem cell line G38 (Supplementary Fig. S6). In these cells and a similarly generated cell line, G35, (5), LY-mediated PI3K inhibition down-regulated elf2\textsubscript{a} phosphorylation, ATF4 protein levels, and system x\textsubscript{-}c\textsuperscript{−} activity (Fig. 6), indicating that the PI3K pathway is involved in the activity of the elf2\textsubscript{a}/ATF4/xCT signaling module in glioblastoma cells in vitro.

High-frequency neuronal activity up-regulates system x\textsubscript{-}c\textsuperscript{−} activity via the PI3K/Akt/GSK-3/β/elf2\textsubscript{a}/ATF4 pathway in primary cortical neurons

In glioblastoma patients, not only was high tumor xCT expression found to be associated with epileptic seizures but also xCT up-regulation in the peritumoral tissue was associated with epilepsy (75), possibly indicating epilepsy-induced changes of the affected brain tissue. To test this hypothesis, we induced high-frequency discharges, as found in epilepsy, in rat cortical neurons using the GABA\textsubscript{A} receptor antagonist bicuculline (Bic) plus the K\textsuperscript{+} channel blocker 4-aminopyridine (Bic/4-AP) (24). Bic/4-AP was reported to activate the PI3K/Akt/GSK-3/β pathway through synaptic N-methyl-D-aspartate receptors in this paradigm (2, 54). Bic/4-AP led to a robust and LY-sensitive increase in system x\textsubscript{-}c\textsuperscript{−} activity as well as xCT mRNA abundance (Fig. 7A, B). In addition, the GSK-3/β inhibitor CT99021 increased xCT mRNA levels (Fig. 7C). The up-regulation of xCT mRNA did not depend on Nrf2, as the Bic/4-AP-mediated induction of xCT mRNA was fully preserved in Nrf2\textsuperscript{−/−} neurons (Fig. 7D). In contrast, Bic/4-AP treatment significantly increased ATF4 protein levels in an LY-sensitive manner (Fig. 7E) and depressed xCT promoter activity in neurons transfected with an xCT activity reporter.
promoter-Luci reporter was suppressed when co-transfected with a dominant-negative ATF4 mutant (Fig. 7G).

**The PI3K/Akt/GSK-3β/eIF2α/ATF4/xCT pathway is activated in hippocampi from patients with temporal lobe epilepsy**

Next, we asked whether the new pathway described here is up-regulated in human hippocampal tissue samples from patients with temporal lobe epilepsy (TLE) obtained during lobectomy. Hypothetically, this should be followed by an increase in extracellular glutamate that is known to decrease the epileptic threshold (15). Indeed, Akt and GSK-3β phosphorylation in epileptic tissue was strongly increased compared with autopic control hippocampi (Fig. 8A). This was associated with a significant increase in eIF2α phosphorylation and ATF4 and xCT protein expression. Linear regression analysis testing the relationship of the four pairs of connected parts of the pathway across the whole group of samples showed positive results for all pairs (Fig. 8B). Importantly, neither Akt, GSK-3β, and eIF2α phosphorylation nor ATF4 and xCT expression were influenced by the postmortem interval in the control group (Fig. 8C).

**Discussion**

The results of the present study tie together two apparently functionally disparate signaling pathways, namely, the PI3K/Akt/GSK-3β pathway and the eIF2α/ATF4/xCT signaling module (Fig. 9). Inhibition of the first pathway by two independent inhibitors, LY and PIK-90, down-regulated the second signaling module. Activation of the PI3K/Akt/GSK-3β pathway leads to the up-regulation of system xc− via eIF2α kinase activation, which in turn activates the eIF2α/ATF4/xCT module, resulting in increased extracellular glutamate, a known epileptogenic factor. This study provides a novel insight into the complex interplay between PI3K/Akt signaling and the AMPK/eIF2α/ATF4/xCT pathway in epilepsy, with potential implications for the development of novel therapeutic strategies.
pathway by insulin, over-expression of a constitutively active PI3K, or mimicking its activation by PIP3, three different GSK-3\(\beta\) inhibitors or GSK-3\(\beta\) knock-down yielded the opposite results. Moreover, in cells unable to phosphorylate eIF2\(\alpha\), the regulation of system xc\(-\) activity by manipulation of the PI3K/Akt/GSK-3\(\beta\) pathway was completely lost. We found evidence of this new connection in cells as diverse as hippocampal HT22 cells, MEFs, glioblastoma cells, and primary neurons and present data strongly supporting the hypothesis that this pathway is responsible for up-regulating xCT expression in the human epileptic hippocampus.

The link between the PI3K/Akt/GSK-3\(\beta\) pathway and the eIF2\(\alpha\)/ATF4/xCT signaling module is the eIF2\(\alpha\) kinase GCN2. This conclusion was drawn from three lines of evidence. First, in HT22 cells, manipulation of the PI3K/Akt/GSK-3\(\beta\) pathway changes GCN2 autophosphorylation, a surrogate marker for its activity (60), consistent with the observed changes in eIF2\(\alpha\) phosphorylation and ATF4 protein levels. Second, the regulation of ATF4 through the PI3K/Akt/GSK-3\(\beta\) pathway is selectively lost in GCN2-deficient cells. Third, the regulation of system xc\(-\) activity in GCN2-deficient cells through the PI3K/Akt/GSK-3\(\beta\) pathway is largely reduced. Classically, GCN2 is activated not only by uncharged tRNAs when amino acids are in limited supply (32) but also by UV radiation (29). Thus, our findings describe a new role for this eIF2\(\alpha\) kinase. However, how the PI3K/GSK-3\(\beta\) pathway regulates GCN2 activity remains to be determined.
The connection between the PI3K/Akt/GSK-3β pathway and the eIF2α/ATF4/xCT signaling module has functional consequences at least in vitro, because through this connection cellular GSH levels and the sensitivity of cells to oxidative glutamate toxicity are regulated. The transcriptional regulation of xCT by the PI3K/GCN2/eIF2α/ATF4 is essential for the pathway to influence cellular GSH and resistance against oxidative stress, as cells expressing xCT that were driven by β actin promoter did not show any difference in GSH or cell death in response to oxidative glutamate toxicity when this pathway was manipulated pharmacologically. This suggests that the PI3K/Akt/GSK-3β/GCN2/eIF2α/ATF4/xCT pathway might be relevant for the cytoprotective consequences of PI3K activation, including neuroprotection against diverse insults (58, 72) although direct evidence for neuroprotective action of xCT induction in vivo is lacking, and it plays a role in the malignant transformation and chemoresistance of tumor cells (21, 62).

However, in addition to GSK-3β inhibition and subsequent neuroprotection via the pathway described here, Akt activation has been described to be neuroprotective by inducing BAD phosphorylation (69) and activation of the mammalian target of rapamycin (41). Due to its high concentration in cells, the GSH/GSSG redox couple determines the general redox environment of cells with a more reduced redox state that is linked to proliferation (67). ATF4 knock-down shifted the GSH/GSSG redox couple to a more oxidized state while inhibiting cell proliferation in a GSH-sensitive manner. Moreover, we show that insulin loses its growth-stimulating effect in fibroblasts lacking eIF2α phosphorylation. These findings strongly support the view that the eIF2α/ATF4/xCT signaling module is an essential constituent of the pro-proliferative machinery downstream of growth factor signaling by keeping the cellular redox potential in a reduced, growth-permissive state. This finding is surprising, as eIF2 phosphorylation has been viewed as a mechanism that reduces protein translation, and therefore growth, in response to cellular stress [reviewed in ref. (56)]. Thus, our data indicate that the formerly accepted role of eIF2α phosphorylation may be overly simplistic and applied only to very high levels of eIF2α phosphorylation.

Glioblastomas exhibit increased PI3K signaling (34), ATF4 (6) and xCT expression (65). The latter has been associated with invasive growth (44) and poor outcome (74) as well as with tumor-induced seizures that are possibly generated by system x− mediated glutamate release (9, 75). Our data show that the connection between the PI3K/Akt/GSK-3β pathway and the eIF2α/ATF4/xCT signaling module is active in human glioblastoma cells which are derived from glioblastoma-initiating cancer stem cells. Thus, PI3K signaling might induce xCT expression via the eIF2α/ATF4 signaling module in glioblastomas and, therefore, tumor-associated seizures. Importantly, the eIF2α/ATF4/xCT branch of PI3K signaling that we describe might also explain other types of seizures. We show that this pathway is also induced by bursts of action potentials as found in epilepsy in primary neurons and in human epileptic hippocampi when compared with non-epileptic controls. Of note, since our control samples were derived from autopsy material and compared with biopsies obtained during lobectomy of the TLE patients, we
cannot exclude changes in protein phosphorylation or expression due to the different tissue handling. However, since these data are highly consistent with the in vitro results and we found no association of the markers examined with the postmortem interval in control tissues, we assume that this potential bias is negligible. Thus, we hypothesize that activation of the PI3K pathway in response to epileptic discharges might result in pro-epileptic molecular changes via induction of eIF2α phosphorylation, ATF4 protein expression, and, finally, up-regulation of system xc⁻ and, therefore, glutamate release.

Materials and Methods

For materials, see Supplementary Materials and Methods.

Human samples

Epileptic patients underwent resection of the hippocampus for medically intractable TLE and were neuropathologically diagnosed to have hippocampal sclerosis of Wyler grade 3 (18) (Supplementary Table S2). Control hippocampal tissue was obtained at autopsy from patients without a history of seizures. There were no significant differences in sex distribution or age between the two groups. Informed consent was obtained for the use of brain tissue and for access to medical records for research purposes. All samples were obtained and used in a manner that was compliant with the Declaration of Helsinki.

Cell culture

HT22 cells were grown in high-glucose Dulbecco’s modified Eagle medium (DMEM) (Invitrogen) that was supplemented with 10% fetal calf serum (FCS; Hyclone) as described earlier (38). HT22 cells were plated in 96-well plates with LY, PIK-90, TGX-221, insulin, CT99021, or LiCl or vehicle or, in the case of LiCl, NaCl. In the case of HT22 cells treated with insulin and CT99021, the serum concentration was reduced to 0.5%, for wild type, and pCAGxCT MEFs medium cystine concentration had to be reduced to 50 μM to induce cell death in pCAGxCT MEFs. After 24 h of culture, the medium was exchanged with fresh medium without the respective compound, and the indicated concentrations of glutamate for 24 h before viability were quantified by the MTT assay as described earlier (38).

eIF2αS9A and wild-type control MEFs (68) were a kind gift from Randal J. Kaufman and Donalyn Scheuner (Sanford-Burnham Institute). Nrf2⁻/⁻ MEFs from Hideyo Sato (Yamagata University), PKR⁻/⁻, PERK⁻/⁻ and GCN2⁻/⁻ MEFs from Antonis Koromilas (McGill University), and HRI⁻/⁻ MEFs from John Bartlett and Megan Sierant (Forsynth Institute). pCAG-xCT MEFs were generated as described in the “Supplementary Materials and Methods” section. MEFs were propagated in high-glucose DMEM (Invitrogen) with 10% FCS (Hyclone) that was additionally supplemented with essential and non-essential amino acids (Invitrogen). Cells were replated for no more than 10 passages by trypsinization when confluent. Glioblastoma-initiating cancer stem cells derived from surgical specimens were grown as described (3). The use of material for cell cultures was approved by the ethics committee, Medical School of Ulm, and informed consent was obtained from the patients before surgery. C35 and G38 glioblastoma-initiating cancer stem cells were differentiated by culture in DMEM (GIBCO by Life Technologies) that was supplemented with 10% FCS (GIBCO), and stem cell-derived glioblastoma cells were passaged by trypsinization for approximately 20 times.

Cortical neurons from E21 Sprague–Dawley rats were cultured as described earlier (2), and mouse cortical neurons from E17.5 Nrf2⁻/⁻ and Nrf2⁺/⁺ mice were cultured as described (20). The Nrf2⁻/⁻ mice were kindly provided by Masayuki Yamamoto of the University of Tsukuba (now University of Tohoku). In both cases, neurons were cultured in growth medium consisting of Neurobasal A that was supplemented with B27 (Invitrogen), 1% rat serum (Harlan SeraLab), and 1 mM glutamine (Sigma-Aldrich). To obtain astrocyte-free neuronal preparations (>98% NeuN-positive neurons and <0.2% GFAP-positive astrocytes), cultures were treated with the anti-mitotic cytosine-arabinoside immediately post-plating. Experiments were performed after 8–10 days in vitro (DIV). Before stimulation, neurons were transferred to a trophically deprived medium containing 10% Minimum Essential Medium (Invitrogen) and 90% Salt/Glucose/Glycine medium consisting of: 114 mM NaCl, 32.7 mM NaHCO₃, 5.292 mM KCl, 1 mM MgCl₂, 2 mM CaCl₂, 10 mM HEPES, 1 mM glycine, 30 mM glucose, 0.5 mM sodium pyruvate, and 0.1% phenol red; osmolarity 325 mOsm/L (2) and allowed to equilibrate for at least 3 h. Bursts of action potentials were induced through stimulation with 50 μM Bic and 250 μM 4-AP for typically 24 h (24) unless stated otherwise.

Transfection and luciferase reporter assays

For luciferase (Luci) reporter assays, HT22 cells were transfected with a pSV-β-galactosidase (Gal) plasmid (Promega) and a vector containing the ATF4 5’UTR and AUG fused to Luci by the TK promoter in a pG3 backbone (22) (a generous gift from David Ron, Metabolic Research Laboratories, University of Cambridge) as previously described (40). When using a pDNA3.1-EGFP construct and 4′-diamidino-2-phenylindole to visualize nuclei, the transfection efficiency was 72.7 ± 8.9% (not shown). Twenty-four hours after transfection, cells were treated with the indicated compounds for 24 h. Next, cells were lysed, and Luci and Gal enzyme activities were measured as previously described (39). For siRNA transfection, HT22 cells were plated in 60 mm dishes at 5×10⁵ cells/dish and 20 pmol ATF4 siRNA (#sc-35113), GSK-3β siRNA (#sc-35525), or control siRNA (#sc-37007), all from Santa Cruz Biotechnology, were used along with Lipofectamine 2000 as previously described (40). Neurons were transfected at DIV 8 using Lipofectamine 2000 as described (2). For xCT-Luci assays, 0.1 μg pTK-Renilla (Promega), 0.2 μg pGL3-4.7 xCT promoter Luci reporter plasmid (63) (a kind gift from Hideyo Sato, Yamagata University), and 0.3 μg of a β-globin control plasmid (a gift from Richard Maurer, Oregon Health Sciences University [71]), or plasmids encoding ATF4 (39) or a dominant negative ATF4 mutant (a gift from Jawed Alam, Ochsner Medical Center [25]) were used. To assay ATF4 5’UTR-mediated translation, the ATF4 5’UTR Luci reporter co-transfected with the pTK-Renilla plasmid (22). Twenty-four hours after transfection, neurons were stimulated as indicated. Luci assays were performed using the Dual Glo assay kit (Promega) with Firefly Luci reporter gene activity normalized to Renilla control.
Enzymatic measurement of GSH

To measure GSH, 1.65 × 10^6 HT22 cells were plated in 60 mm dishes and grown in the presence of 10 μM LY or vehicle for 24 h. Total GSH was measured as described (45). To measure the GSSG/GSH ratio, the GSH/GSSG-Glo Assay kit (Promega) was used.

Measurement of system x_c^- activity

3 × 10^4 HT22 cells were seeded into 24-well plates and treated with LY, LiCl or NaCl, or insulin for 24 h and PIK-90 for 15 h. System x_c^- activity after 24 h of PIK-90 exposure returned to normal levels (data not shown), either due to instability of the compound or due to up-regulation of PI3Ks other than PI3Kz. For insulin and CT99021, FCS concentration was reduced to 0.5%. 6 × 10^4 eIF2αS51A MEFS, Nrf2^-/-, GCN2^-/- MEFS, or control MEFS with or without 10 μM LY, 1 μM PIK-90, or vehicle (dimethylsulfoxide) with 20 mM LiCl or NaCl were grown for 24 h. For primary cortical neurons, each Western blot was repeated at least three independent protein samples.

PI3Ks UPREGULATE SYSTEM x_c^- VIA eIF2α AND ATF4

RNA preparation, reverse transcription, and qPCR

Total RNA from HT22 cells was isolated using the RNAeasy mini kit (Qiagen). qPCR that was used to quantify ATF4 and xCT mRNA expression was performed as previously described (40). For primers used for qPCR for the cDNAs encoding the four p110 isoforms, see the “Supplementary Materials and Methods” section. RNA from primary cortical neurons was prepared using the Roche isolation reagents, including a 15 min DNase I treatment to avoid genomic DNA contamination of samples (Roche). cDNA was synthesized using the Transcriptor One-Step RT-PCR Kit (Roche). qPCR was performed in an Mx3000P qPCR System (Stratagen; Agilent Technologies) using 2 × FastStart Universal SYBR Green Master Mix (Roche) according to the manufacturer’s instructions. Expression of the gene of interest was calculated using the efficiency corrected ΔΔCt method, normalizing to either GAPDH or 18S ribosomal RNA as housekeeping genes. For primers used for qPCR for cDNA derived from primary neurons, see the “Supplementary Materials and Methods” section.

Statistical analysis

Data from at least three independent experiments were normalized, pooled, and analyzed using Graph Pad Prism 4 software followed by appropriate statistical tests. For exclusion of outliers, the established definition of an extreme outlier was used as follows: values lower or higher than the 25% percentile (Q1) or 75% percentile (Q3) minus or plus three times the interquartile range (Q3–Q1), respectively.

Acknowledgments

E.A. was funded by National Epilepsy Funds, NEF 09-05; G.E.H. by the Medical Research Council, the Wellcome Trust, and the Biotechnology and Biological Research Council; P.M. by Diabetes UK; J.V.L. is supported by the agency for Innovation by Science and Technology (IWT/SB/101344). J.V.L., I.S., and A.M. acknowledge the Fund for Scientific Research Flanders (FWO, Belgium, grant G038412N) and the Queen Elizabeth Medical Foundation (G.S.K.E.) for financial support. The authors are grateful to Masayuki Yamamoto for providing the Nrf2^-/- mice.

Author Disclosure Statement

The authors declare that they have no conflicts of interest to disclose.

References

2. Al-Mubarak B, Soriano FX, and Hardingham GE. Synaptic NMDAR activity suppresses FOXO1 expression via a cis-


52. Murphy TH, Miyamoto M, Sastre A, Schnaar RL, and Coyle JT. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. *Neuron* 2: 1547–1558, 1989.


Address correspondence to:
Dr. Jan Lewerenz
Department of Neurology
Ulm University
Ooberer Eselsberg 45
Ulm 89081
Germany
E-mail: jan.lewerenz@googlemail.com

Dr. Pamela Maher
Cellular Neurobiology Laboratory
Salk Institute for Biological Studies
10010 N. Torrey Pines Road
La Jolla, CA 92037

E-mail: pmaher@salk.edu

Date of first submission to ARS Central, May 30, 2013; date of final revised submission, October 25, 2013; date of acceptance, November 12, 2013.

Abbreviations Used

- 4-AP = 4-aminopyridine
- 4-CPG = (S)-4-carboxyphenylglycine
- 5’UTR = 5’ untranslated region
- ANOVA = analysis of variance
- ATF4 = activating transcription factor 4
- Bic = bicuculline
- BIO = (2’Z,3’E)-6-bromoindirubin-3’-oxime
- CFSE = carboxyfluorescein diacetate
- succinimidyl ester
- DIV = days in vitro
- DMSO = dimethylsulfoxide
- EDTA = ethylenediaminetetraacetic acid
- eIF2α = eukaryotic initiation factor 2α
- FCS = fetal calf serum
- GABA = γ-aminobutyric acid
- Gal = β-galactosidase
- GCN2 = general control non-derepressible-2
- GEE = glutathione ethyl ester
- GFAP = glial fibrillary acidic protein
- GSH = glutathione
- GSK-3β = glycogen synthase kinase 3β
- GSSG = glutathione disulfide
- HCA = homocysteic acid
- HRI = heme-regulated eIF2α kinase
- IRS = integrated stress response
- LiCl = lithium chloride
- mBIO, MeBIO = methyl-BIO
- MEF = mouse embryonic fibroblast
- Nrf2 = nuclear factor (erythroid-derived 2)-like 2
- ORF = open reading frame
- PBS = phosphate-buffered saline
- PERK = PKR-like endoplasmic reticulum kinase
- PI3K = phosphoinositide 3-kinase
- PI3P = phosphoinositide 3,4,5-triphosphate
- PKR = protein kinase R
- qPCR = quantitative polymerase chain reaction
- RT = room temperature
- SAS = sulfasalazine
- SDS = sodium dodecyl sulfate
- SEM = standard error of the mean
- TBS = Tris-buffered saline
- TLE = temporal lobe epilepsy